CLINICAL_TRIALS ClinicalTrials.gov record update

A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02602067
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:09.119455+00:00
Published At: 2018-09-18T00:00:00+00:00
Record Updated At: 2018-09-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Breast Neoplasm", "Head and Neck Neoplasm", "Skin Neoplasm", "Respiratory Tract Neoplasm", "Urogenital Neoplasm", "Digestive System Neoplasm", "Pancreatic Neoplasm", "Connective and Soft Tissue Neoplasm", "Lymphoma, Non-Hodgkin"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-09-18"
protocolSection.identificationModule.nctId: "NCT02602067"
protocolSection.identificationModule.officialTitle: "A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.